Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in Patients With Inflammatory Rheumatic Diseases (HZ-REUMA)
NCT06763783Phase 4Enrolling by invitation
- Sponsor
- Region Skåne
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Region Skåne. Started Dec 2024; status: enrolling by invitation.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06763783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763783.